This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khattak, S. Articles by Koren, G. Search for Related Content PubMed PubMed Citation Articles by Khattak, S. Articles by Koren, G. Social Bookmarking                   What's this?

Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients

John W. Rogan, MSc

Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto; The University of Toronto, Ontario, Canada

E. Fred Saunders, MD

Division of Hematology and Oncology, The Hospital for Sick Children, Toronto; The University of Toronto, Ontario, Canada

Jochen G. W. Theis, MD

Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto; The University of Toronto, Ontario, Canada

Gerald S. Arbus, MD

Division of Nephrology, The Hospital for Sick Children, Toronto; The University of Toronto, Ontario, Canada

Gideon Koren, MD

Division of Clinical Pharmacology and Toxicology, Department of Paediatrics, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8; The University of Toronto, Ontario, Canada

The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ±2.1 mmHg and 117.2 ±2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 +1.8 mmHg and 75.5 ±2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. T. Flynn, M. C. Nahata, J. D. Mahan Jr, R. J. Portman, and for the PATH-2 Investigators Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J. Clin. Pharmacol., August 1, 2006; 46(8): 905 - 916. [Abstract] [Full Text] [PDF]